Nociceptor neurons affect cancer immunosurveillance
Mohammad Balood, Maryam Ahmadi, Tuany Eichwald, Ali Ahmadi, Abdelilah Majdoubi, Karine Roversi, Katiane Roversi, Christopher T Lucido, Anthony C Restaino, Siyi Huang, Lexiang Ji, Kai-Chih Huang, Elise Semerena, Sini C Thomas, Alexandro E Trevino, Hannah Merrison, Alexandre Parrin, Benjamin Doyle, Daniel W Vermeer, William C Spanos, Caitlin S Williamson, Corey R Seehus, Simmie L Foster, Hongyue Dai, Chengyi J Shu, Manu Rangachari, Jacques Thibodeau, Sonia Del Rincon, Ronny Drapkin, Moutih Rafei, Nader Ghasemlou, Paola D Vermeer, Clifford J Woolf, and Sebastien Talbot.
Nature
, Nov 2022
cancer
neuroimmunology
Solid tumours are innervated by nerve fibres that arise from the
autonomic and sensory peripheral nervous systems1-5. Whether the
neo-innervation of tumours by pain-initiating sensory neurons
affects cancer immunosurveillance remains unclear. Here we show
that melanoma cells interact with nociceptor neurons, leading to
increases in their neurite outgrowth, responsiveness to noxious
ligands and neuropeptide release. Calcitonin gene-related
peptide (CGRP)-one such nociceptor-produced
neuropeptide-directly increases the exhaustion of cytotoxic CD8+
T cells, which limits their capacity to eliminate melanoma.
Genetic ablation of the TRPV1 lineage, local pharmacological
silencing of nociceptors and antagonism of the CGRP receptor
RAMP1 all reduced the exhaustion of tumour-infiltrating
leukocytes and decreased the growth of tumours, nearly tripling
the survival rate of mice that were inoculated with B16F10
melanoma cells. Conversely, CD8+ T cell exhaustion was rescued
in sensory-neuron-depleted mice that were treated with local
recombinant CGRP. As compared with wild-type CD8+ T cells,
Ramp1-/- CD8+ T cells were protected against exhaustion when
co-transplanted into tumour-bearing Rag1-deficient mice.
Single-cell RNA sequencing of biopsies from patients with
melanoma revealed that intratumoral RAMP1-expressing CD8+ T
cells were more exhausted than their RAMP1-negative
counterparts, whereas overexpression of RAMP1 correlated with a
poorer clinical prognosis. Overall, our results suggest that
reducing the release of CGRP from tumour-innervating nociceptors
could be a strategy to improve anti-tumour immunity by
eliminating the immunomodulatory effects of CGRP on cytotoxic
CD8+ T cells.